OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in Virology is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)

Article	Citations
Structure of SARS-CoV-2 spike protein	135
Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19	123
Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection	102
Recent advances in antiviral drug development towards dengue virus	76
Future considerations for the mRNA-lipid nanoparticle vaccine platform	64
Current challenges to virus discovery by meta-transcriptomics	62
Zoonotic disease and virome diversity in bats	59
Global overview and major challenges of host prediction methods for uncultivated phages	57
Structure and function of SARS-CoV-2 polymerase	54
Animal models for SARS-CoV-2	54
Coronavirus entry: how we arrived at SARS-CoV-2	53
The virome of vector mosquitoes	53
Dengue vaccine development by the year 2020: challenges and prospects	50
A structural view of the SARS-CoV-2 virus and its assembly	50
A new generation of vaccines based on alphavirus self-amplifying RNA	49
The healthy human virome: from virus–host symbiosis to disease	48
RNA viruses and the cGAS-STING pathway: reframing our understanding of innate immune sensing	46
Protective and enhancing interactions among dengue viruses 1-4 and Zika virus	45
Cell-to-cell movement of plant viruses via plasmodesmata: a current perspective on potyviruses	43
Engineering therapeutic phages for enhanced antibacterial efficacy	42
Recent advances in understanding plant antiviral RNAi and viral suppressors of RNAi	41
Viral Z-RNA triggers ZBP1-dependent cell death	40
COVID-19, the first pandemic in the post-genomic era	39
Structure, function and assembly of the long, flexible tail of siphophages	39
European regulatory aspects of phage therapy: magistral phage preparations	37

Host cell-intrinsic innate immune recognition of SARS-CoV-2	37
Influenza D virus	35
Perspective on taxonomic classification of uncultivated viruses	34
Anti-viral protective capacity of tissue resident memory T cells	34
Dengue mouse models for evaluating pathogenesis and countermeasures	34
Interfering with SARS-CoV-2: are interferons friends or foes in COVID-19?	34
Entry of influenza A virus into host cells — recent progress and remaining challenges	34
Risk factors and biomarkers of severe dengue	33
Mitigation of evolved bacterial resistance to phage therapy	31
Tombusviruses orchestrate the host endomembrane system to create elaborate membranous replication organelles	31
Detection of viruses by inflammasomes	30
Viral structural proteins as targets for antivirals	29
Adenovirus – a blueprint for gene delivery	29
Rotavirus cell entry: not so simple after all	29
Current view and perspectives in viroid replication	28
Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy	28
Drug resistance mutations in HIV: new bioinformatics approaches and challenges	28
Animal models of SARS-CoV-2 transmission	27
Phage banks as potential tools to rapidly and cost-effectively manage antimicrobial resistance in the developing world	26
Hepatitis B virus–host interactions and novel targets for viral cure	26
Extracellular vesicles in virus infection and pathogenesis	26
Epigenetic control of the Epstein-Barr lifecycle	26
Natural killer cells and unconventional T cells in COVID-19	26
Immune system control of hepatitis C virus infection	25
Cytomegalovirus as an immunomodulator across the lifespan	25
Progress and pitfalls of a year of drug repurposing screens against COVID-19	25
Digital phagograms: predicting phage infectivity through a multilayer machine learning approach	24
Proteases and variants: context matters for SARS-CoV-2 entry assays	22
Development of plant-made monoclonal antibodies against viral infections	22
R gene mediated defense against viruses	22
Historical discourse on the development of the live attenuated tetravalent dengue vaccine candidate TV003/TV005	22
The long and winding road: human papillomavirus entry and subcellular trafficking	22
Mapping the diverse structural landscape of the flavivirus antibody repertoire	22
Molecular dynamics of the viral life cycle: progress and prospects	21
Principles of epithelial homeostasis control during persistent human papillomavirus infection and its deregulation at the cervical transformation zone	21
An overview of the current state of phage therapy for the treatment of biofilm-related infections	21
Tissues: the unexplored frontier of antibody mediated immunity	21
Targeting of viral RNAs by Upf1-mediated RNA decay pathways	21
Measles immunity and immunosuppression	21
The gut virome in inflammatory bowel diseases	21
Assembly of the virome in newborn human infants	20
UPR signaling at the nexus of plant viral, bacterial, and fungal defenses	20
Phage therapy for secondary bacterial infections with COVID-19	20
Remdesivir for the treatment of Covid-19: the value of biochemical studies	19
Shopping for phages? Unpacking design rules for therapeutic phage cocktails	19
Revisiting an old friend: new findings in alphavirus structure and assembly	19
Virus genomics: what is being overlooked?	19
Antiviral immunity triggered by infection-induced host transposable elements	18
Human genetic and immunological dissection of papillomavirus-driven diseases: new insights into their pathogenesis	18
Unresolved questions in the zoonotic transmission of MERS	18

Evolution of the interferon response: lessons from ISGs of diverse mammals	18
Broadly neutralizing antibodies against HIV-1 and concepts for application	18
Rhabdoviruses as vectors for vaccines and therapeutics	18
Dengue virus infection and Nrf2 regulation of oxidative stress	18